Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease

Archives of Internal Medicine

Volumn 166, Issue 7, 2006, Pages 797-805

  Thornley Brown, Denyse ^a,l   Wang, Xuelei ^b   Wright Jr , Jackson T ^c   Randall, Otelio S ^d   Miller, Edgar R ^e,g   Lash, James P ^h   Gassman, Jennifer ^b   Contreras, Gabriel ⁱ   Appel, Lawrence J ^f   Agodoa, Lawrence Y ^j   Cheek, DeAnna ^k  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d HOWARD UNIVERSITY HOSPITAL   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g NATIONAL INSTITUTE ON AGING   (United States)

^h UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

ⁱ UNIVERSITY OF MIAMI   (United States)

^j NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^k MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^l University of Alabama at Birmingham   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; FUROSEMIDE; GLUCOSE; METOPROLOL; MINOXIDIL; RAMIPRIL;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RENOVASCULAR HYPERTENSION; RISK ASSESSMENT; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AFRICAN AMERICANS; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; HYPERTENSION, RENAL; INCIDENCE; MALE; METOPROLOL; MIDDLE AGED; MULTICENTER STUDIES; RAMIPRIL; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS;

EID: 33645751576     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.166.7.797     Document Type: Article

References (38)

1. Division of Health Interview Statistics, National Center for Health Statistics, Centers for Disease Control and Prevention. Data from the National Health Interview Survey. Available at: http://www.cdc.gov/diabetes/pubs/ estimates.htm#prev5. Accessed February 1, 2006.
2. Harris MI. Is the risk of diabetic retinopathy greater in non-Hispanic blacks and Mexican Americans than in non-Hispanic whites with type 2 diabetes? a U.S. population study. Diabetes Care. 1998;21:1230-1235.
3. Harris MI. Epidemiological correlates of DM in Hispanics, whites, and blacks in the U.S. population. Diabetes Care. 1991;14:639-648.
4. Tull ES, Roseman JM. Diabetes in African-Americans. In: National Diabetes Data Group, eds. Diabetes in America. 2nd ed. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases; 1995:613-625.
5. US Renal Data System. USRDS 2003 Annual Data Report. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases; 2003.
6. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal syndrome. N Engl J Med. 1996;334:374-381.
7. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism. 1990;39:167-174.
8. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med. 1987;317:350-357.
9. Shen DC, Shieh SM, Fuh MM, Wu DA, Chen YD, Reaven GM. Resistance to insulin-stimulated -glucose uptake in patients with hypertension. J Clin Endocrinol Metab. 1988;66:580-583.
10. Zavaroni I, Mazza S, Dall'aglio E, Gasparini P, Passeri M, Reaven GM. Prevalence of hyperinsulinaemia in patients with high blood pressure. J Intern Med. 1992;231:235-240.
11. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insights from the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 2003;107:1291-1296.
12. Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. JAMA. 2001;286:1882-1885.
13. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-616.
14. Lindholm LH, Ibsen H, Dahlof B, et al; LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:1004-1010.
15. Lindholm LH, Perrson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003;21:1563-1574.
16. Lindholm LH, Ibsen H, Borch-Johnsen K, et al; Life Study Group. Risk of new-onset diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study. J Hypertens. 2002;20:1879-1886.
17. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
18. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-2816.
19. Julius S, Kjeldsen S, Weber M, et al; VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-2031.
20. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-2431.
21. Agodoa LY, Appel LJ, Bakris G, Beck G, Bourgoignie J; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719-2728.
22. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28:1039-1057.
23. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27(suppl 1):S5-S10.
24. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
25. Wright JT Jr, Dunn JK, Cutler JA, et al; ALLHAT Collaborative Research Group. Outcomes in hypertensive blacks and non-blacks treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293:1595-1608.
26. Edelstein SL, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to DM: an analysis of six prospective studies. Diabetes. 1997;46:701-710.
27. de Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA. 2001;285:2109-2113.
28. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233-240.
29. Bjørnholt JV, Erikssen G, Aaser E, et al. Fasting blood glucose: an underestimated risk factor for cardiovascular death: results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care. 1999;22:45-49.
30. deFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin resistance in uremia. J Clin Invest. 1981;67:563-570.
31. Fliser D, Pacini G, Engeleiter R, et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int. 1998;53:1343-1347.
32. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
33. Chiasson JL, Josse R, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-DM randomised trial. Lancet. 2002;359:2072-2077.
34. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963-969.
35. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus α-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;42:239-246.
36. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity: the Swedish Trial in Old Patients With Hypertension-2 study. Lancet. 1999;354:1751-1756.
37. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet. 2003;362:1527-1535.
38. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95:29-35.